Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 14/20 | 1.00 |
| ▸ | GSK3B | P49841 | 14/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 11/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 10/20 | 1.00 |
| ▸ | CDK1 | P06493 | 5/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 4/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 4/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 1.00 |
| ▸ | CDK2 | P24941 | 4/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 3/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | CTRB1 | P17538 | 2/20 | 1.00 |
| ▸ | AHR | P35869 | 2/20 | 1.00 |
| ▸ | CDK4 | P11802 | 2/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 2/20 | 1.00 |
| ▸ | CCND1 | P24385 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CDK14 | O94921 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CDK11B | P21127 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30094663 | 0.84 | GSK3A (1.00) | GSK3AGSK3BCDK5CDK5R1CDK1 | |
| SCHEMBL30597679 | 0.84 | GSK3A (1.00) | GSK3AGSK3BCDK5CDK5R1CDK1 | |
| SCHEMBL29648491 | 0.84 | GSK3A (1.00) | GSK3AGSK3BCDK5CDK5R1CDK1 | |
| SCHEMBL30273058 | 0.84 | GSK3A (1.00) | GSK3AGSK3BCDK5CDK5R1CDK1 | |
| SCHEMBL29975793 | 0.84 | GSK3A (1.00) | GSK3AGSK3BCDK5CDK5R1CDK1 | |
| SCHEMBL30319807 | 0.84 | GSK3A (1.00) | GSK3AGSK3BCDK5CDK5R1CDK1 | |
| SCHEMBL30597674 | 0.84 | GSK3A (1.00) | GSK3AGSK3BCDK5CDK5R1CDK1 | |
| SCHEMBL30380971 | 0.83 | GSK3A (0.70) | GSK3AGSK3BCDK5CDK5R1CDK1 | |
| SCHEMBL23064865 | 0.82 | CDK2 (1.00) | GSK3AGSK3BCDK5CDK5R1CDK1 | |
| SCHEMBL29353719 | 0.82 | CDK2 (1.00) | GSK3AGSK3BCDK5CDK5R1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3583644-B1 | ELECTRODE MATERIALS AND PROCESSES FOR THEIR PREPARATION | HYDRO QUEBEC (CA) | 2024-08-07 | — | — | EP | claimed |
| CN-114540278-A | Microvessel in-vitro culture method and culture solution | 青岛大学 | 2022-05-27 | — | — | CN | claimed |
| EP-4633612-A1 | FIXED DOSE COMBINATION COMPRISING NETUPITANT AND PALONOSETRON | Alfred E. Tiefenbacher (GmbH & Co. KG) (DE) | 2025-10-22 | — | — | EP | disclosed |
| EP-4633608-A1 | ANTIOXIDANT-FREE FIXED DOSE COMBINATION OF NETUPITANT AND PALONOSETRON | Alfred E. Tiefenbacher (GmbH & Co. KG) (DE) | 2025-10-22 | — | — | EP | disclosed |
| CN-115851780-B | Flavin monooxygenase gene ScFMO, protein coded by same and application thereof | 中国人民解放军海军军医大学 | 2025-04-15 | — | — | CN | disclosed |
| US-20240252688-A1 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. | 2024-08-01 | — | — | US | disclosed |
| WO-2024126398-A1 | FIXED DOSE COMBINATION COMPRISING NETUPITANT AND PALONOSETRON | ALFRED E. TIEFENBACHER (GMBH & CO. KG) (DE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024126408-A1 | ANTIOXIDANT-FREE FIXED DOSE COMBINATION OF NETUPITANT AND PALONOSETRON | ALFRED E. TIEFENBACHER (GMBH & CO. KG) (DE) | 2024-06-20 | — | — | WO | disclosed |
| US-20240034799-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | CEDARS SINAI MEDICAL CENTER (US) | 2024-02-01 | — | — | US | disclosed |
| EP-4256086-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | Cedars-Sinai Medical Center (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230279491-A1 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER | 2023-09-07 | — | — | US | disclosed |
| US-11511028-B2 | Extracorporeal drug removal for intravascular triggered drug delivery systems | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2022-11-29 | — | — | US | disclosed |
| CN-115397452-A | Lung biomarkers and methods of use thereof | 普罗科技有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20220354845-A1 | METHODS FOR ENHANCING DNA DAMAGE AND APOPTOSIS OF LEUKEMIC CELLS | UNIV JEFFERSON (US) | 2022-11-10 | — | — | US | disclosed |
| CN-114933585-A | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2022-08-23 | — | — | CN | disclosed |
| CN-108026159-B9 | BTLA fusion protein agonists and uses thereof | 桑福德伯纳姆普利斯医学发现研究所 | 2022-07-05 | — | — | CN | disclosed |
| WO-2022119842-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER (US) | 2022-06-09 | — | — | WO | disclosed |
| CN-108026159-B | BTLA fusion protein agonists and uses thereof | 桑福德伯纳姆普利斯医学发现研究所 | 2022-05-27 | — | — | CN | disclosed |
| US-11318138-B2 | Methods for treating B cell proliferative disorders | CORNELL UNIVERSITY (US) | 2022-05-03 | — | — | US | disclosed |
| CN-114206392-A | Immunomodulatory agent antibody drug conjugates and uses thereof | 苏特罗生物制药公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318138-B2 | Methods for treating B cell proliferative disorders | CDK4, BCL6, BCL6B | GSK3A 308/4885GSK3B 198/4885CDK5 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.